• 1. An alternative biorefinery approach to address microalgal seasonality: blending with spent coffee grounds
  Andre Prates Pereira,Tao Dong,Eric P. Knoshaug,Nick Nagle,Ryan Spiller,Bonnie Panczak,Christopher J. Chuck,Philip T. Pienkos Sustainable Energy Fuels, 2020,4, 3400-3408
• 2. An intensified π-hole in beryllium-doped boron nitride meshes: its determinant role in CO2 conversion into hydrocarbon fuels?
  Luis Miguel Azofra,Douglas R. MacFarlane,Chenghua Sun Chem. Commun., 2016,52, 3548-3551
• 3. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 4. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

Recent Advances in the Study of 2-Chloro-N-cyclopropyl-5-(trifluoromethyl)pyrimidin-4-amine (CAS: 1050602-61-3)

2-Chloro-N-cyclopropyl-5-(trifluoromethyl)pyrimidin-4-amine (CAS: 1050602-61-3) is a pyrimidine derivative that has garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential as a key intermediate in the synthesis of bioactive molecules. Recent studies have explored its applications in drug discovery, particularly in the development of kinase inhibitors and antimicrobial agents. This research brief aims to summarize the latest findings related to this compound, highlighting its synthetic utility, biological activity, and potential therapeutic applications.

One of the most notable advancements in the study of 2-Chloro-N-cyclopropyl-5-(trifluoromethyl)pyrimidin-4-amine is its role as a building block for the synthesis of novel kinase inhibitors. Kinases are critical targets in cancer therapy, and the trifluoromethyl group in this compound enhances its binding affinity to kinase active sites. Recent publications have demonstrated its use in the development of selective inhibitors for EGFR (Epidermal Growth Factor Receptor) and VEGFR (Vascular Endothelial Growth Factor Receptor), which are implicated in various cancers. The compound's unique structural features, including the cyclopropylamine moiety, contribute to improved pharmacokinetic properties and reduced off-target effects.

In addition to its applications in oncology, 2-Chloro-N-cyclopropyl-5-(trifluoromethyl)pyrimidin-4-amine has shown promise in antimicrobial research. A 2023 study published in the Journal of Medicinal Chemistry reported its incorporation into novel pyrimidine-based antimicrobial agents with potent activity against drug-resistant bacterial strains, including MRSA (Methicillin-Resistant Staphylococcus aureus). The trifluoromethyl group was found to enhance membrane permeability, while the chloro substituent contributed to target specificity. These findings underscore the compound's versatility in addressing global health challenges posed by antimicrobial resistance.

The synthetic pathways for 2-Chloro-N-cyclopropyl-5-(trifluoromethyl)pyrimidin-4-amine have also been optimized in recent years. A 2022 study in Organic Process Research & Development detailed a scalable, high-yield synthesis route using palladium-catalyzed cross-coupling reactions, which significantly reduced production costs and improved purity. This advancement is particularly relevant for industrial-scale applications, where cost-effectiveness and reproducibility are critical. Furthermore, computational studies have provided insights into the compound's reactivity, enabling more efficient derivatization for structure-activity relationship (SAR) studies.

Despite these promising developments, challenges remain in the clinical translation of derivatives based on 2-Chloro-N-cyclopropyl-5-(trifluoromethyl)pyrimidin-4-amine. Issues such as metabolic stability and potential toxicity profiles require further investigation. Ongoing research is focused on optimizing the compound's scaffold to address these limitations while retaining its bioactive properties. Collaborative efforts between academia and industry are expected to accelerate the development of next-generation therapeutics leveraging this versatile pyrimidine derivative.

In conclusion, 2-Chloro-N-cyclopropyl-5-(trifluoromethyl)pyrimidin-4-amine (CAS: 1050602-61-3) continues to be a valuable tool in medicinal chemistry, with expanding applications in kinase inhibition and antimicrobial therapy. Recent synthetic and biological studies have highlighted its potential, paving the way for future innovations in drug discovery. As research progresses, this compound is likely to play an increasingly important role in addressing unmet medical needs.

• 638168-61-3(4-Pyrimidinamine, 2-chloro-5-methyl-N-propyl-)
• 702637-57-8(4-Pyrimidinamine, 2-chloro-N-2-propynyl-5-(trifluoromethyl)-)
• 1050602-57-7((2-Chloro-5-methyl-pyrimidin-4-yl)-cyclopropyl-amine)
• 515824-43-8(2-chloro-N-methyl-5-(trifluoromethyl)pyrimidin-4-amine)
• 26243-43-6(N-benzyl-2-chloro-5-(trifluoromethyl)pyrimidin-4-amine)
• 1496016-04-6(4-Pyrimidinamine, 2-chloro-5-methyl-N-(1-methylpropyl)-)
• 1217500-49-6(4-Pyrimidinamine, 2-chloro-N-cyclobutyl-5-methyl-)
• 1217500-47-4(2-Chloro-N-isopropyl-5-methylpyrimidin-4-amine)
• 1480295-17-7(4-Pyrimidinamine, 2-chloro-N-cyclohexyl-5-methyl-)
• 1374829-47-6(4-Chloro-N-ethyl-5-(trifluoromethyl)pyrimidin-2-amine)